Inventor · disambiguated record
Bradlee David Germain
Also filed as: GERMAIN BRADLEE DAVID
12 granted patents·4 pending applications·16 citations·filing 2013–2021
86Inventor score
Files withCAYMAN CHEMICAL CO INC16
Top patents by PatentIndex Score
16 records- 0186US9487478B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2015·Granted Nov 8, 2016·4 cites·21 claims
- 0285US9180116B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2013·Granted Nov 10, 2015·6 cites·20 claims
- 0382US9440919B2Difluorolactam compositions for EP4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2013·Granted Sep 13, 2016·4 cites·23 claims
- 0480US9701630B2Difluorolactam compositions for EP4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2016·Granted Jul 11, 2017·2 cites·20 claims
- 0577US11884624B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2021·Granted Jan 30, 2024·0 cites·3 claims
- 0673US11066361B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2020·Granted Jul 20, 2021·0 cites·3 claims
- 0767US10556862B2Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2018·Granted Feb 11, 2020·0 cites·4 claims
- 0866US11345690B2Methods of synthesizing a difluorolactam analogCAYMAN CHEMICAL CO INC·Filed 2019·Granted May 31, 2022·0 cites·3 claims
- 0960US9914725B2Methods of synthesizing a difluorolactam analogCAYMAN CHEMICAL CO INC·Filed 2014·Granted Mar 13, 2018·0 cites·4 claims
- 1059US2017066751A1Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2016·Application pending·0 cites
- 1155US2019144435A1Difluorolactam compositions for ep4-mediated osteo related diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2019·Application pending·0 cites
- 1254US2018170918A1Methods of synthesizing a difluorolactam analogCAYMAN CHEMICAL CO INC·Filed 2018·Application pending·0 cites
- 1353US2017260173A1Difluorolactam compositions for ep4-mediated osteo related diseases and condtionsCAYMAN CHEMICAL CO INC·Filed 2017·Application pending·0 cites
- 1449US10729810B2Methods, systems, and compositions for promoting bone growthCAYMAN CHEMICAL CO INC·Filed 2014·Granted Aug 4, 2020·0 cites·16 claims
- 1547US9676712B2Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2014·Granted Jun 13, 2017·0 cites·24 claims
- 1642US9688627B2Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsCAYMAN CHEMICAL CO INC·Filed 2014·Granted Jun 27, 2017·0 cites·24 claims
Join the waitlist — get patent alerts
Get an alert when Bradlee David Germain files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →